miR-21 Targets Fas Ligand-mediated Apoptosis in Breast Cancer Cell Line MCF-7

被引:0
|
作者
吴明富 [1 ]
杨洁 [1 ]
项涛 [1 ]
史艳燕 [2 ]
刘丽江 [1 ]
机构
[1] Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
[2] Department of Anesthesiology, Pu’ai Hospital, Tongji Medical College, Huazhong University of Science and Technology
基金
中国国家自然科学基金;
关键词
tumor immunotherapy; breast tumor; FasL; miR-21;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
100214 ;
摘要
Over-expression of Fas ligand(FasL) on tumor cell surface can induce the apoptosis of spe cific activated tumor infiltrating lymphocytes(TILs) via the Fas/FasL pathway, leading to the formation of a site of immune privilege surrounding the tumor mass for escaping immune surveillance and pro moting tumor proliferation, invasion and metastasis. The blocking effect of miR-21 on FasL-mediated apoptosis in breast cancers was investigated in this study. The expression levels of miR-21 and FasL in human breast carcinoma cell lines were detected by using RT-PCR and Western blotting. FasL as a tar get gene of miR-21 was identified by Luciferase assay. The apoptosis of Jurkat T lymphocytes induced by MCF-7 cells was determined by flow cytometry. It was found that in four human breast cancer cel lines, FasL expression level in MCF-7 cells was the highest, while miR-21 was down-regulated the mos notably. After miR-21 expression in MCF-7 cells was up-regulated, FasL was identified as a target gene of miR-21. When the effector/target(E/T) ratio of MCF-7 cells and Jurkat cells was 10:1, 5:1 and 1:1the inhibitory rate of apoptosis of Jurkat T lymphocytes induced by MCF-7 cells was 95.81%, 93.16%and 91.94%, respectively. It is suggested that in breast cancers miR-21 expression is negatively associ ated with FasL expression, and FasL is a target gene of miR-21. miR-21 targeting and regulating FasL-mediated apoptosis will bring us the possibility of a new tumor immunotherapy via breaking tu mor immune privilege.
引用
收藏
页码:190 / 194
页数:5
相关论文
共 50 条
  • [21] Opioids and the apoptotic pathway in MCF-7 breast cancer cell line
    Gach, Katarzyna
    Szemraj, Janusz
    Wyrebska, Anna
    Janecka, Anna
    PHARMACOLOGICAL REPORTS, 2011, 63 (01) : 234 - 234
  • [22] Antiproliferative effect of dexamethasone in the MCF-7 breast cancer cell line
    Buxant, Frederic
    Kindt, Nadege
    Laurent, Guy
    Noel, Jean-Christophe
    Saussez, Sven
    MOLECULAR MEDICINE REPORTS, 2015, 12 (03) : 4051 - 4054
  • [23] Clotrimazole Sensitizes MCF-7 Breast Cancer Cell Line to Radiation
    Garcia, L.
    Tambasco, M.
    MEDICAL PHYSICS, 2016, 43 (06) : 3620 - 3620
  • [24] Evolution of Genomic Diversity in the Breast Cancer Cell Line MCF-7
    den Hollander, P.
    Osadchey, I
    Hampton, O. A.
    Coarfa, C.
    Milosavljevic, A.
    Lee, A., V
    CANCER RESEARCH, 2009, 69 (24) : 702S - 703S
  • [25] MCF-7, A BREAST-CANCER CELL LINE RESPONSIVE TO PROLACTIN
    BURKE, RE
    GAFFNEY, EV
    IN VITRO-JOURNAL OF THE TISSUE CULTURE ASSOCIATION, 1977, 13 (03): : 188 - 188
  • [26] Cytotoxicity of liposomal paclitaxel in breast cancer cell line MCF-7
    Esfahani M.K.M.
    Alavi S.E.
    Movahedi F.
    Alavi F.
    Akbarzadeh A.
    Indian Journal of Clinical Biochemistry, 2013, 28 (4) : 358 - 360
  • [27] Methionine cytotoxicity in the human breast cancer cell line MCF-7
    Hyung H. Kim
    Chung S. Park
    In Vitro Cellular & Developmental Biology - Animal, 2003, 39 : 117 - 119
  • [28] Methionine cytotoxicity in the human breast cancer cell line MCF-7
    Kim, HH
    Park, CS
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2003, 39 (3-4) : 117 - 119
  • [29] Weightlessness acts on human breast cancer cell line MCF-7
    Vassy, J
    Portet, S
    Beil, M
    Millet, G
    Fauvel-Lafève, F
    Gasset, G
    Schoevaert, D
    SPACE LIFE SCIENCES: GRAVITATIONAL BIOLOGY: 2002, 2003, 32 (08): : 1595 - 1603
  • [30] Effects of two abietanes on MCF-7 breast cancer cell line
    Pedro, M
    Gaspar-Marques, C
    Simoes, MFA
    Pinto, M
    Nascimento, MSJ
    Proceedings of the Joint Meeting on Medicinal Chemistry, 2005, : 147 - 151